← Patent Expiry Watch
October 14, 2026 · Patent expires April 22, 2034
Brukinsa (Zanubrutinib): The 2034-2037 Generic Opportunity Window
BeiGene's blockbuster second-generation BTK inhibitor Brukinsa (zanubrutinib) generated $2.19B in 2024 (+106% YoY). The core US substance patent (US 10,570,139) expires on April 22, 2034. A Hatch-Waxman Paragraph IV settlement with MSN Laboratories licenses generic market entry on June 15, 2037, defining a multi-tiered generic opportunity window while the brand remains 100% exclusive today.
What we do
We track expirations like this continuously
This is one drug, picked for today's post. A Portfolio Retainer watches an entire portfolio or compound class on an ongoing basis and flags new matching filings as they publish.